Mix-up Of Two Anti-Hypertension Drugs Sold In U.S. Prompts India's Lupin To Recall Product
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - One of India's leading pharmaceutical companies Lupin Laboratories Ltd. has initiated a recall of its key ACE inhibitor lisinopril. Lupin had U.S. sales of roughly $45 million from the single drug, said a source closely tracking the news
You may also be interested in...
Outsourcing Your Way Into Trouble: Pfizer Issues Recall After Indian Aurobindo Mislabels Bottles
India-based Aurobindo Pharma Ltd. may find itself in a little hot water with business partner Pfizer Inc. after forcing a recall because bottles of an anti-depressant drug may have been mislabeled as a benign prostatic hyperplasia treatment
14 Months After U.S. FDA Charged India's Lupin, Manufacturing Facility At Mandideep Cleared
MUMBAI - A long trail of hair splitting audits and investigations came to an end for India's drug maker Lupin as U.S. FDA issued an "All Clear" statement for the company's Mandideep manufacturing site in the central Indian state of Madhya Pradesh
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).